Friday, 16 October 2026European Markets

ABN AMRO BANK N.V. Stock Bullish Momentum With A 9% Rise At Session Start Today

Loading stream...

(VIANEWS) - Shares of ABN AMRO BANK N.V. (AEX-Index: ABN.AS) jumped 9.3% to 15.98 € at 10:09 EST on Wednesday, following the last session's downward trend. AEX-Index is rising 0.05% to 753.45 €, following the last session's upward trend. This seems, at the moment, a somewhat bullish trend trading session today.

About ABN AMRO BANK N.V.

ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ABN AMRO BANK N.V. has a trailing twelve months EPS of $2.15.

PE Ratio

ABN AMRO BANK N.V. has a trailing twelve months price to earnings ratio of 7.43. Meaning, the purchaser of the share is investing $7.43 for every dollar of annual earnings.

Volume

Today's last reported volume for ABN AMRO BANK N.V. is 7134736 which is 177.11% above its average volume of 2574610.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

ABN AMRO BANK N.V.'s stock is considered to be overbought (>=80).

More news about ABN AMRO BANK N.V. (ABN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com